DRUG DELIVERY TO THE LUNGS: ISSUES OF CONCERN
https://doi.org/10.18093/0869-0189-2011-0-1-107-110
Abstract
Drug delivery to the lungs: issues of concern
About the Authors
V. V. Arkhipov
Первый МГМУ им. И.М.Сеченова
Russian Federation
Russian Federation
д. м. н., проф. кафедры клинической фармакологии и пропедевтики внутренних болезней
119991, Москва, ул. Трубецкая, 8, стр. 2
тел.: (495) 966-54-14
N. G. Berdnikova
Первый МГМУ им. И.М.Сеченова
Russian Federation
Russian Federation
к. м. н., доцент кафедры клинической фармакологии и пропедевтики внутренних болезней
119991, Москва, ул. Трубецкая, 8, стр. 2
тел.: 8-985-190-17-00
I. P. Polyakova
ГКБ № 23 им. "Медсантруд"
Russian Federation
Russian Federation
врач
109240, Москва, ул. Яузская, 11
References
1. Cates C.J., Crilly J.A., Rowe B.H. Holding chambers (spacers) versus nebulisers for beta agonist treatment of acute asthma. Cochrane Database Syst. Rev. 2006, Issue 2. Art.No.: CD000052. DOI: 10.1002/14651858.CD000052.pub2
2. Parkin P.C., Saunders N.R., Diamond S.A. et al. Randomised trial spacer v nebuliser for acute asthma. Arch. Dis. Child.1995; 72 (3): 239–240.
3. Amirav I., Newhouse M.T. Aerosol therapy in infants and toddlers: past, present and future. Exp. Rev. Respir. Med.2008; 2 (5): 597–605.
4. Bisca N., Cernatescu I., Dragomir D. et al. Comparison of the efficacy and safety of beclometasone dipropionate suspension for nebulization and beclometasone dipropionatevia a metered-dose inhaler in paediatric patients with moderate to severe exacerbation of asthma. Respir. Med. 2003;97 (Suppl. B): S15–S20.
5. Devadason S.G., Huang Т., Walker S. et al. Distribution of technetium 99m labelled QVAR delivered using an Autohaler device in children. Eur. Respir. J. 2003; 21:1007–1010.
6. Tal A., Golan H., Grauer N.et al. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J. Pediatr. 1996; 128: 479–484.
7. Jackson V. Pulmicort. International product monograph.AstraZeneca Global; 2008. 95.
8. Marguet C., Couderc L., Le Roux P. et al. Inhalation treatment: errors in application and difficulties in acceptance of the devices are frequent in wheezy infants and young children. Pediatr. Allergy Immunol. 2001; 12 (4): 224–230.
9. Janssens H.M., van der Wiel E.C., Verbraak A.F. et al.Aerosol therapy and the fighting toddler: is administration during sleep an alternative? J. Aerosol Med. 2003; 16 (4):395–400.
10. Schuepp K.G., Devadason S.G., Roller C. et al. Aerosol delivery of nebulised budesonide in young children with asthma.Respir. Med. 2009; 103: 1738–1745.
11. Salmon B., Wilson N.M., Silverman M. How much aerosol reaches the lungs of wheezy infants and toddlers? Arch. Dis.Child. 1990; 65: 401–403.
12. Chua H.L., Collis G.G., Newbury A.M. et al. The influence of age on aerosol deposition in children with cystic fibrosis.Eur. Respir. J. 1994; 7: 2185–2191.
13. Meyer Т., Brand Р., Ehlich Н. et al. Deposition of Foradil Pin human lungs: comparison of in vitro and in vivo data.J. Aerosol Med. March 2004: 43–49.
14. Thorsson L., Edsbacker S. Less variability in lung deposition of budesonide via Turbuhaler® than of fluticasone via Diskus® / Accuhaler® and pMDI in adults. Am. J. Respir.Crit. Care Med. 2003; 167 (Suppl. 7): A896.
15. Mallol J., Rattray S., Walker G. et al. Aerosol deposition in infants with cystic fibrosis. Pediatr. Pulmonol. 1996; 21:276–281.
16. Wildhaber J.H., Dore N.D., Wilson J.M. et al. Inhalation therapy in asthma; Nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J. Pediatr. 1999; 135: 28–33
17. Camargo C.A., Ramachandran S., Ryskina K.L. et al. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am. J. Hlth Syst. Pharm. 2007; 64:1054–1060.
18. McLaughlin T., Leibman C., Patel P., Camargo С.А. Risk of recurrent emergency department visits or hospitalizations in children with asthma receiving nebulized budesonide inhalation suspension compared with other asthma medications. Curr. Med. Res. Opin. 2007; 23 (6):1319–1328.
19. Engel T., Heinig J.M., Medsen F., Nikander K. Peak inspiratory flowrate and inspiratory vital capacity of patients with asthma measured with and without a new dry powder inhaler device (Turbuhaler). Eur. Respir. J. 1990; 3:1037–1041.
20. Dewar M.H., Jamieson A., McLean A., Crompton GK. Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir. Med. 1999; 93: 342–344.
21. Pedersen S., Hansen O.R., Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis.Child. 1990; 65: 308–310.
22. Weuthen T., Roeder S., Brand P. et al. In vitro testing of two formoterol dry powder inhalers at different flow rates.J. Aerosol Med. 2002; 15: 297–303.
23. Nielsen K.G., Auk I.L., Bojsen K. et al. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur. Respir. J. 1998; 11:350–354.
24. Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers?J. Aerosol. Med. 1995; 8 (Suppl. 3): S13–S19.
25. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of β2 agonist particle size. Am. J. Respir. Crit. Care Med.2005; 172: 1497–1504.
26. Giraud V., Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur.Respir. J. 2002; 19: 246–251.
Review
For citations:
Arkhipov V.V., Berdnikova N.G., Polyakova I.P. DRUG DELIVERY TO THE LUNGS: ISSUES OF CONCERN. PULMONOLOGIYA. 2011;(1):107-110. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-1-107-110
Views:
656
Email this article 